GlassScriptPhysician profile
Stefan C Hemmings
NPI 1760820575
$4,545.55
in general payments reported to CMS, 2019-2025
27 companies · $650 in 2025
The $650 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $418 · 2021: $600 · 2022: $799 · 2023: $872 · 2024: $826 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,242 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,242.13 |
| Education | $106.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $421.82 | 2021-2025 | |
| Travere Therapeutics, INC. | $412.85 | 2022-2025 | |
| Vifor Pharma, INC. | $411.39 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $349.04 | 2020-2024 | Acthar |
| Opko Pharmaceuticals, LLC | $330.31 | 2019-2024 | Rayaldee |
| Amgen INC. | $313.80 | 2019-2024 | Tavneos, Krystexxa, Parsabiv |
| Fresenius USA Marketing, INC. | $299.97 | 2019-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $270.47 | 2019-2025 | Farxiga |
| Calliditas Therapeutics US INC. | $243.03 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $233.56 | 2021-2025 | Benlysta, Arexvy, Shingrix |
| Horizon Therapeutics Plc | $221.20 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $166.02 | 2019-2025 | Jynarque |
| Akebia Therapeutics INC | $138.86 | 2019-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.01 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $117.40 | 2021-2024 | Lupkynis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $102.56 | 2024 | |
| Novartis Pharmaceuticals Corporation | $80.09 | 2023-2024 | |
| Ultragenyx Pharmaceutical INC. | $69.37 | 2020-2023 | |
| Mallinckrodt Enterprises LLC | $54.39 | 2019 | |
| Alnylam Pharmaceuticals INC. | $37.47 | 2021 | |
| Genentech USA, INC. | $31.20 | 2025 | |
| Ardelyx, INC. | $29.25 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $22.11 | 2022 | |
| Lilly USA, LLC | $19.09 | 2024 | Jardiance |
| Alexion Pharmaceuticals, INC. | $18.25 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $15.87 | 2022 | |
| Bard Peripheral Vascular, INC. | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Hemmings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.